CanSino Biologics Inc. (HKG:6185)
33.88
-0.06 (-0.18%)
At close: Mar 9, 2026
CanSino Biologics Employees
CanSino Biologics had 1,115 employees as of June 30, 2025. The number of employees increased by 10 or 0.90% since the number was reported on December 31, 2024.
Employees
1,115
Change
10
Growth
0.90%
Revenue / Employee
1.08M HKD
Profits / Employee
28.07K HKD
Market Cap
13.72B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Consun Pharmaceutical Group | 3,073 |
| CF PharmTech | 574 |
| Sihuan Pharmaceutical Holdings Group | 2,767 |
| Luye Pharma Group | 5,115 |
| Shandong Xinhua Pharmaceutical Company | 7,159 |
| China Traditional Chinese Medicine Holdings Co. | 15,583 |
| Sunshine Lake Pharma | 4,861 |
| Shanghai Fudan-Zhangjiang Bio-Pharmaceutical | 899 |
CanSino Biologics News
- 4 days ago - Meningitis Shot Delivers Dose Of Good Cheer For CanSino - Benzinga
- 4 weeks ago - CanSinoBIO at WGS 2026: Accelerating Global Access to Innovative Vaccines - PRNewsWire
- 11 months ago - CanSino Biologics CEO on earnings, business outlook, and international partnerships - CNBC
- 3 years ago - World-First Inhaled COVID-19 Vaccine, Developed in Partnership Between Aerogen® and CanSinoBIO, First Public Booster Immunization in China. - Business Wire
- 3 years ago - China's CanSinoBIO H1 revenue drops on weaker COVID shot demand - Reuters
- 4 years ago - CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing - PRNewsWire
- 4 years ago - CanSinoBIO Rebrands to Reflect Commitment to Life Sciences Research - PRNewsWire
- 4 years ago - CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China - PRNewsWire